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Abstract
Background: HIV-1 and Mycobacterium tuberculosis cause substantial morbidity and mortality. Despite the
availability of antiretroviral and antituberculosis treatment in Africa, clinical deterioration during antituberculosis
treatment remains a frequent reason for hospital admission. We therefore determined the incidence, causes and
risk factors for clinical deterioration.
Methods: Prospective cohort study of 292 adults who initiated antituberculosis treatment during a 3-month
period. We evaluated those with clinical deterioration over the following 24 weeks of treatment.
Results: Seventy-one percent (209/292) of patients were HIV-1 infected (median CD4+: 129 cells/μL [IQR:62-277]).
At tuberculosis diagnosis, 23% (34/145) of HIV-1 infected patients qualifying for antiretroviral treatment (ART) were
receiving ART; 6 months later, 75% (109/145) had received ART. Within 24 weeks of initiating antituberculosis
treatment, 40% (117/292) of patients experienced clinical deterioration due to co-morbid illness (n = 70),
tuberculosis related illness (n = 47), non AIDS-defining HIV-1 related infection (n = 25) and AIDS-defining illness
(n = 21). Using HIV-1 uninfected patients as the referent group, HIV-1 infected patients had an increasing risk of
clinical deterioration as CD4+ counts decreased [CD4+>350 cells/μL: RR = 1.4, 95% CI = 0.7-2.9; CD4+:200-350 cells/
μL: RR = 2.0, 95% CI = 1.1-3.6; CD4+<200 cells/μL: RR = 3.0, 95% CI = 1.9-4.7]. During follow-up, 26% (30/117) of
patients with clinical deterioration required hospital admission and 15% (17/117) died. Fifteen deaths were in HIV-1
infected patients with a CD4+<200 cells/μL.
Conclusions: In multivariate analysis, HIV-1 infection and a low CD4+ count at tuberculosis diagnosis were
significant risk factors for clinical deterioration and death. The initiation of ART at a CD4+ count of <350 cells/μL
will likely reduce the high burden of clinical deterioration.
Background
Adherence to antituberculosis treatment in advanced
human immunodeficiency virus type 1 (HIV-1) infection
results in rapid sterilisation of sputum, radiographic
improvement and a low risk of relapse [1]. The benefits
of antiretroviral treatment (ART) in reducing HIV-1
replication and restoring pathogen-specific immunity are
well described [2,3]. Despite the availability of antituber-
culosis and antiretroviral treatment in Africa, clinical
deterioration during antituberculosis treatment in HIV-1
infected patients remains an important reason for hospi-
tal admission and death [4,5].
Profoundly immune-suppressed HIV-1 infected
patients may encounter a complicated clinical course
after starting antituberculosis treatment. While initiation
of ART during antituberculosis treatment reduces mor-
tality [6], the optimal interval from antituberculosis
treatment to initiation of ART is not known. Early
initiation of ART restores pathogen-specific immunity,
but also significantly increases the risk of the tuberculo-
sis-associated immune reconstitution inflammatory syn-
drome (TB-IRIS) [7]. Conversely, a delay in initiation of* Correspondence: dominiquepepper@gmail.com
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ART may allow additional AIDS-defining illnesses to
manifest. Other reasons for clinical deterioration during
antituberculosis treatment include antimicrobial resis-
tance, suboptimal antituberculosis drug concentrations,
drug reactions, and other opportunistic illnesses [8,9].
The greatest burden of HIV-1 infection and tuberculo-
sis occurs in resource-limited settings, such as South
Africa, where health systems are overwhelmed and rapid
diagnostic tools are not readily available. In 2006,
337,400 of 482,000 tuberculosis patients in South Africa
were HIV-1 co-infected and 105,000 tuberculosis deaths
were reported [10]. The fatal consequences of HIV-1/
Mycobacterium tuberculosis co-infection are well
described [11,12]. However, the incidence of clinical
deterioration during antituberculosis treatment amongst
HIV-1 infected patients (compared to HIV-1 uninfected
patients) is unknown. Determining the causes and risk
factors for clinical deterioration during antituberculosis
treatment may inform initiatives to reduce the burden
on both tuberculosis and ART programmes.
In this study, we assessed patients at initiation of anti-
tuberculosis treatment and followed them for 24 weeks,
in order to determine the incidence, causes and risk fac-
tors for clinical deterioration. We also discuss initiatives
to reduce the high burden of clinical deterioration in
resource-limited settings.
Methods
We conducted a prospective cohort study at Khayelitsha
Site B tuberculosis clinic (Cape Town, South Africa)
from 1 June 2008 through 15 February 2009. We
assessed adult (≥ 18 years age) patients diagnosed with
tuberculosis at Khayelitsha Site B tuberculosis clinic
from 1 June 2008 through 31 August 2008 (3-month
assessment period). Informed consent was obtained
from all enrolled patients. HIV-1 voluntary counselling
and testing is offered to all patients diagnosed with
tuberculosis at Site B Khayelitsha. Patients were fol-
lowed for 24 weeks from initiation of antituberculosis
treatment. Our study was nested within a tuberculosis
drug susceptibility testing (DST) survey in which first-
line DST (for isoniazid and rifampin) was routinely per-
formed, regardless of HIV-1 status or previous tubercu-
losis. The Research Ethics Committee of the University
of Cape Town approved this study (REC 178/2008).
Study site and setting
Khayelitsha Site B tuberculosis clinic is a primary-level
outpatient health care facility, which serves ~100,000
people within its high-density, low-income catchment
area. Approximately 1,200 adult cases of tuberculosis
are diagnosed per annum at Site B tuberculosis clinic.
In 2006, the antenatal HIV-1 seroprevalence in this
community was 33% (95%: 29.1 - 36.9%) [13]. According
to national protocol, patients with a new diagnosis of
tuberculosis receive 6 months of daily antituberculosis
treatment (isoniazid, rifampin, pyrazinamide, and etham-
butol for 2 months, followed by isoniazid and rifampin
for 4 months) [14]. The retreatment regimen is: isonia-
zid, rifampin, pyrazinamide, ethambutol, and streptomy-
cin for 2 months, followed by isoniazid, rifampin,
pyrazinamide, and ethambutol for 1 month, and then
isoniazid, rifampin, and ethambutol for 5 months. First-
line ART in South Africa is stavudine, lamivudine, and
either nevirapine or efavirenz. Efavirenz is preferred for
patients who are receiving rifampin-based antituberculo-
sis treatment. Patients with a CD4+ cell count <200
cells/μL and/or a history of a World Health Organiza-
tion (WHO) stage 4 illness, other than extra-pulmonary
tuberculosis, are eligible to commence ART [15]; ART
is typically commenced 2 months after initiation of anti-
tuberculosis treatment. If the CD4+ cell count is <50
cells/μL or a serious HIV-1-related illness is present,
ART may be commenced 2 weeks after starting antitu-
berculosis treatment [15]. To date, >5,000 people have
initiated ART at Khayelitsha Site B HIV clinic.
Definitions
“Tuberculosis patients” refers to patients diagnosed with
tuberculosis and initiated on antituberculosis treatment.
We defined microbiologically-confirmed tuberculosis as
Mycobacterium tuberculosis cultured or acid-fast bacilli
visualised in a biological specimen. Biological specimens
included sputum, pleural fluid, urine, nodal aspirates,
pericardial aspirates and cerebrospinal fluid. We defined
microbiologically-unconfirmed tuberculosis according to
the WHO case definitions for smear-negative and extra-
pulmonary tuberculosis [16]. Biological specimens were
obtained at tuberculosis diagnosis, at 8 and 20 weeks’
follow-up and at clinical deterioration. First-line DST
using the GenoType MTBDRplus assay [17] was per-
formed on biological specimens that were smear-positive
for acid-fast bacilli and/or culture positive for Mycobac-
terium tuberculosis. We defined multidrug-resistant
(MDR) tuberculosis as M. tuberculosis resistant to iso-
niazid and rifampin.
We defined clinical deterioration as symptomatic wor-
sening or failure to stabilise within 24 weeks following
initiation of antituberculosis treatment. We subdivided
the causes of clinical deterioration into HIV-1 related
illnesses and HIV-1 unrelated illnesses. HIV-1 related
causes included AIDS defining illnesses (according to
WHO stage 4 criteria [18]), and non AIDS-defining ill-
nesses i.e. Non-AIDS defining HIV-1 related infections.
HIV-1 unrelated illnesses included tuberculosis related
illnesses, and illnesses unrelated to tuberculosis i.e. co-
morbid illnesses. Tuberculosis-related illnesses included
MDR-TB, deterioration due to poor adherence,
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paradoxical tuberculosis-associated immune reconstitution
inflammatory syndrome (TB-IRIS) and paradoxical reac-
tions. A co-morbid illness was an acute illness that
occurred after tuberculosis diagnosis and was considered
not to be directly attributable to HIV-1 or tuberculosis. A
co-morbid illness also included an acute deterioration of a
pre-existing condition. For example, we regarded diabetic
ketoacidosis in a diabetic patient as a co-morbid illness.
We defined paradoxical TB-IRIS according to the con-
sensus clinical case definition for resource-limited set-
tings [7]. We defined paradoxical reactions using an
adaptation of this consensus clinical case definition of
paradoxical TB-IRIS [7]. Three criteria were required
for a diagnosis of paradoxical reaction:
1. Diagnosis of tuberculosis (microbiologic confirma-
tion or according to WHO criteria [16]) with initial
response to antituberculosis treatment,
2. The recurrence/new onset of tuberculosis disease
manifestations within 24 weeks of antituberculosis
treatment, and
3. Exclusion of alternative explanations for clinical
deterioration (such as antituberculosis drug resis-
tance, poor adherence, drug toxicity or reaction, or
an additional infection).
Paradoxical reactions were diagnosed in both HIV-1
infected and uninfected patients. HIV-1 infected patients
receiving ART at clinical deterioration were diagnosed
with paradoxical TB-IRIS rather than a paradoxical reac-
tion according to our definitions.
We defined a patient as being lost to follow-up if we
were unable to trace a patient 24 weeks after initiation
of antituberculosis treatment. We used clinic and hospi-
tal medical notes, as well as the National Health Labora-
tories Service database to trace specimens and the
Provincial Government of the Western Cape’s electronic
tuberculosis register to trace patients.
Assessment of patients with clinical deterioration
The study was discussed with physicians and nurses at
the tuberculosis clinic prior to commencement of the
study. Adult patients with clinical deterioration within
24 weeks of initiation of antituberculosis treatment were
prospectively evaluated (regardless of severity of illness,
eventual diagnosis, or inpatient or outpatient manage-
ment) to determine the reason for clinical deterioration.
Stable patients were assessed at Khayelitsha Site B
tuberculosis clinic; patients requiring hospital admission
or invasive outpatient procedures were assessed at GF
Jooste Hospital (the clinic’s referral hospital). At clinical
deterioration, we routinely obtained biological speci-
mens to investigate drug-resistant M. tuberculosis. Spe-
cimens were also cultured for bacterial organisms.
Data collection and analysis
Data collected included demographic information,
tuberculosis specimen results, HIV-1 status, antiretro-
viral treatment, CD4+ cell count at tuberculosis diagno-
sis, diagnosis at clinical deterioration and outcome 24
weeks after initiation of antituberculosis treatment. Sta-
tistical analyses were performed using Stata 10.0 (Texas,
USA). Wilcoxon rank-sum and Kruskall-Wallis tests
were used for group comparisons, and Fisher’s exact
tests for proportion comparisons. Variables with the
outcome of interest were entered into Cox proportional
hazards models to assess the independent effects of cov-
ariates. We censored patients at clinical deterioration
when performing Cox-proportional hazards model ana-
lysis and relative risk calculations. Significant variables
were removed from the model to assess whether these
effects remained. The assumptions of the Cox model
were verified; non-informative censoring was performed
and the tests for the proportional hazards assumption
were not significant. We censored patients at loss to fol-
low-up when determining the incidence rate of clinical
deterioration (illnesses diagnosed per 100 months of fol-
low-up). Individual patients could contribute more than
one event in the calculation of the incidence rate.
Results
During the 3-month assessment period (figure 1), 305
adults (≥ 18 years age) initiated antituberculosis treat-
ment, 7 of whom had untraceable clinical records and 6
of whom declined HIV-1 testing. We restricted our data
analysis to the 292 (96%) patients whose HIV-1 status
and clinic records were available. In 209 HIV-1 infected
and 83 HIV-1 uninfected patients, loss to follow-up (46
[22%] of 209 vs. 29 [35%] of 83, p-value = 0.026) and
mortality (16 [8%] of 209 vs. 1 [1%] of 83, p-value =
0.048) differed significantly at 24 weeks.
At initial tuberculosis diagnosis (table 1), HIV-1
infected patients were more likely than HIV-1 unin-
fected patients to be female, be of younger age, have
extra-pulmonary tuberculosis and be diagnosed with
tuberculosis at the referral hospital. HIV-1 uninfected
patients were more likely than HIV-1 infected patients
to have microbiologic confirmation of tuberculosis at
initial tuberculosis diagnosis and during the 24 weeks of
follow-up.
Prior to tuberculosis diagnosis, 34 (23%) of 145 HIV-1
infected patients who qualified for ART under national
guidelines were receiving ART. Six months later, 109
(75%) of 145 patients had received ART.
Causes of Clinical Deterioration and Hospital Admission
During the 24 weeks of follow-up, 117 (40%, 95% CI:
35-46%) of 292 tuberculosis patients experienced clinical
deterioration, of whom 101 were HIV-1 infected and 16
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were HIV-1 uninfected. Causes of clinical deterioration
(table 2) included: co-morbid illnesses (70 patients),
tuberculosis-related illnesses (47 patients), non AIDS-
defining HIV-1 related infections (25 patients) and
AIDS-defining illnesses (21 patients). Peripheral neuro-
pathy, enteric illness and deep venous thrombosis were
frequent co-morbid illnesses. TB-IRIS and paradoxical
reactions were frequent tuberculosis-related illnesses.
Oesophageal candida, Pneumocystis jirovecii pneumonia
and cryptococcal meningitis were frequent AIDS-defin-
ing illnesses. Of 117 patients who experienced dete-
rioration, 30 (26%) required hospital admission [27
(27%) of 101 HIV infected and 3 (19%) of 16 HIV-1
uninfected patients (p-value = 0.756)]. Causes of inpati-
ent hospital admission were paradoxical reaction or
TB-IRIS (9 patients), new AIDS-defining illness
(8 patients), deep venous thrombosis (6 patients),
MDR-TB (2 patients), cardiomyopathy (1 patient),
pneumothorax (1 patient), symptomatic deterioration
due to poor adherence with antituberculosis treatment
(1 patient), hyperglycaemic emergency (1 patient) and
seizure disorder (1 patient).
Risk Factors for Clinical Deterioration
In the 292 tuberculosis patients, 4 factors were signifi-
cantly associated with clinical deterioration in univariate
analysis: HIV-1 infection, diagnosis of tuberculosis at
the referral hospital, evidence of extra-pulmonary tuber-
culosis, and absence of a DST result at tuberculosis
diagnosis. Only HIV-1 infection (figure 2a) remained
significant in multivariate analysis (adjusted hazard ratio
[aHR]= 2.0, 95% CI = 1.1-3.6).
In subsequent analysis (figures not shown), we
assessed whether the probability of clinical deterioration
from non-HIV-1 related causes was associated with
HIV-1 infection. In univariate analysis, we found a sig-
nificant association between HIV-1 infection and non-
HIV-1 related causes for deterioration (RR = 1.3, 95%
305 Adults (> 18 years) started TB chemotherapy from 1 June through 31 August 2008 
7 records untraceable  
6 declined HIV testing 
292 HIV-1 status known1 
209 HIV-1 infected2 83 HIV-1 uninfected 
1 died 
29 lost to follow-up 
16 died 
46 lost to follow-up 
147 completed 24 
weeks of follow-up 
53 completed 24 
weeks of follow-up 
Figure 1 Flow-diagram of 305 adult patients who started antituberculosis treatment from 1 June - 31 August 2008. 1Subsequent data
analysis for 292 patients with known HIV-1 status 2CD4 counts not performed in 3 of 209 HIV-1 infected patients
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CI: 1.07 - 1.50). However, in the Cox proportional
hazards model, using the same variables as figure 2a,
this significant association was not confirmed (HR = 1.5,
95% CI: 0.81-2.64). This analysis suggests that HIV-1
infection is a significant variable for clinical deteriora-
tion because of HIV-1 related illnesses (either AIDS- or
non AIDS-defining illnesses).
In the 209 HIV-1 infected tuberculosis patients, 3 fac-
tors were significantly associated with clinical deteriora-
tion in univariate analysis: a lower CD4+ count,
diagnosis of tuberculosis at the referral hospital, and
antiretroviral treatment received during antituberculosis
treatment. Only a lower CD4+ stratum at tuberculosis
diagnosis (figure 2b) remained significant in multivariate
analysis (aHR = 1.5, 95% CI = 1.1-2.2).
In subsequent analysis (figures not shown), we
assessed whether the probability of clinical deterioration
from non-HIV-1 related causes was associated with
decreasing CD4+ counts. We did not find a significant
association between decreasing CD4+ count strata and
non-HIV-1 related causes in both the univariate analysis
(P = 0.189) and the Cox proportional hazards model
(HR = 1.3, 95%CI: 0.88 - 1.97). This analysis suggests
that decreasing CD4+ counts are a significant risk factor
for clinical deterioration because of their association
with HIV-1 related illnesses (either AIDS- or non AIDS-
defining illnesses).
Relative Risk and Incidence Rate of Clinical Deterioration
HIV-1 infection and a low CD4+ count were the only
significant risk factors for clinical deterioration in multi-
variate analysis. We therefore determined the relative
risk and incidence rate of clinical deterioration accord-
ing to HIV-1 status and CD4+ stratum. HIV-1 infected
patients were more likely than HIV-1 uninfected
patients to experience clinical deterioration (RR = 2.6,
95%CI: 1.6-4.0). Using HIV-1 uninfected patients as the
referent group, the relative risk (RR) of clinical dete-
rioration increased as the CD4+ counts in HIV-1
infected patients decreased (CD4+ >350 cells/μL: RR =
1.4, 95% CI = 0.7-2.9; CD4+200-350 cells/μL: RR = 2.0,
95% CI = 1.1-3.6; CD4+ <200 cells/μL: RR = 3.0, 95%
CI = 1.9-4.7). The incidence rate (IR) of clinical dete-
rioration (illnesses diagnosed per 100 months of follow-
up) also increased as the CD4+ counts decreased. Inci-
dence rates differed significantly between HIV-1 unin-
fected patients (IR = 5.1, 95% CI = 3.1-7.5) and HIV-1
infected patients with a CD4+ count of 200-350 cells/μL
(IR = 12.3, 95% CI = 8.2-17.0). Similarly, incidence rates
differed significantly between HIV-1 infected patients
with a CD4+ count of 200-350 cells/μL and HIV-1
infected patients with a CD4+ count < 200 cells/μL (IR =
20.7, 95% CI 17.8-23.9).
Figure 3 is a Lowess plot showing the proportion of
patients who experienced clinical deterioration during
Table 1 Baseline characteristics and microbiologic confirmation of tuberculosis in 209 HIV-1 infected and 83 HIV-1
uninfected patients receiving antituberculosis treatment
HIV-1 infected
(n = 209)
HIV-1 uninfected
(n = 83)
p-value
Female, n (%) 112 (54) 25 (30) <0.001
Age in years, median (IQR) 35 (30-41) 38 (29-49) 0.035
CD4 count at TB diagnosis, n (%):
>350 cells/mm3 36 (17) -
200 - 350 cells/mm3 37 (18) -
< 200 cells/mm3 133 (64) -
Not performed 3 (1) -
Previous TB, n (%) 71 (34) 19 (23) 0.070
TB diagnosed at referral hospital, n (%): 79 (38) 13 (16) <0.001
Microbiologic confirmation at TB diagnosis1, n (%) 123 (59) 68 (82) <0.001
Drug susceptibilities known at TB diagnosis1, n (%) 67 (32) 49 (59) <0.001
Culture sent at TB diagnosis, n (%) 169 (81) 68 (82) 1.000
Extra-pulmonary TB, n (%): 82 (39) 14 (17) <0.001
Weight at TB diagnosis in kg, median (IQR) 54 (49-62) 54 (49-64) 0.644
Microbiologic confirmation at TB diagnosis and during 24 weeks of follow-up2, n (%) 153 (73) 70 (84) 0.048
Drug susceptibilities known at TB diagnosis and during 24 weeks of follow-up2, n (%) 117 (56) 57 (69) 0.296
Culture sent at TB diagnosis and/or during 24 weeks of follow-up, n (%) 190 (91) 76 (92) 1.000
Key:
1within 14 days of TB diagnosis. No TB specimens sent in 12 HIV-1 infected patients and 3 HIV-1 uninfected patients at TB diagnosis.
2no TB specimens sent in 2 HIV-1 infected patients.
TB = tuberculosis, IQR = inter-quartile range, OR = odds-ratio, 95% CI = 95% confidence interval.
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the 24 weeks of antituberculosis treatment. The initial
peak at 6 weeks in HIV-1 uninfected patients corre-
sponds with tuberculosis-related illnesses (mostly para-
doxical reactions) and the baseline fluctuations
represent co-morbid illnesses. The curve for HIV-1
infected patients with a CD4+ count > 350 cells/μL is
similar to that of HIV-1 uninfected patients, despite an
earlier peak for paradoxical reactions. The proportion of
HIV-1 infected patients with a CD4+ count of 200-350
cells/μL who experienced clinical deterioration substan-
tially increased after 10 weeks of follow-up. Further-
more, a substantially higher proportion of HIV-1
infected patients with a CD4+ count <200 cells/μL
experienced clinical deterioration compared to other
CD4+ strata.
Mortality
Fifteen of 17 deaths occurred in HIV-1 infected patients
with a CD4+ count < 200 cells/μL. The median interval
from antituberculosis treatment to death was 98 days
(IQR = 59 -128). Eight of 17 deaths occurred between
10 and 20 weeks of follow-up. Diagnoses at time of
death included: AIDS-defining illnesses (5), poor adher-
ence with antituberculosis treatment (4), paradoxical
neurologic TB-IRIS (3), enteric illness (2), MDR-TB (1),
pulmonary embolus (1) and tension pneumothorax (1).
Loss to follow-up
Within 24 weeks of commencing antituberculosis treat-
ment, 75 patients were lost to follow-up. The median
interval from antituberculosis treatment to loss to
Table 2 Illnesses (n = 199) in 101 HIV-1 infected and 16 HIV-1 uninfected patients who experienced clinical
deterioration during 24 weeks of antituberculosis treatment
HIV-1 infected HIV-1 uninfected
number of illnesses = n, (total number of patients = pnts) 180 (101) 19 (16)
1. Tuberculosis related illnesses, n (pnts) 49 (43) 5 (5)
TB-IRIS 22 -
Paradoxical reaction 17 4
MDR-TB1 4 1
Deterioration due to poor adherence 5 -
Low rifampin concentration in comparison to the recommended range 1 -
2. AIDS-defining illnesses, n (pnts) 29 (21) -
Oesophageal candida 11 -
Pneumocystis jiroveci pneumonia2 5 -
Cryptococcal meningitis 4 -
Cytomegalovirus retinitis 3 -
Other3 6 -
3. Non-AIDS defining HIV-1 related infections, n (pnts) 27 (25) -
Superficial herpes infection4 9 -
Bacterial infection5 9 -
Fungal (oral/vaginal/superficial) infection 9 -
4. Co-morbid illnesses, n (pnts) 76 (59)6 14 (11)7
Key:
TB = tuberculosis; TB-IRIS = TB-associated immune reconstitution inflammatory syndrome
1MDR-TB: Mycobacterium tuberculosis resistant to rifampin and isoniazid
2All 5 patients diagnosed with Pneumocystis jirovecii pneumonia received trimethoprim sulfamethoxazole chemoprophylaxis (160/800 mg daily).
3Other = HIV-1 associated nephropathy (2), HIV-1 associated encephalopathy (2), Disseminated Kaposi’s sarcoma (2)
45 patients diagnosed with herpes simplex, 4 patients diagnosed with herpes zoster (all < 1 month duration)
5Urinary tract infection (3) - E. coli, Klebsiella sp., enterococcus; Pelvic inflammatory disease (3); H. influenza pneumonia (1); otitis media (1); carbuncle (1)
676 illnesses diagnosed in 59 patients:
CD4 > 350 cells/mm3 = 7 illnesses diagnosed in 7 patients: deep venous thrombosis (2); sacroiliitis (1); acute asthmatic attack (1); cardiomyopathy (1); severe
epistaxis (1); supra-condylar fracture (1),
CD4200 - 350 cells/mm3 = 12 illnesses diagnosed in 7 patients: enteric illness with no pathogen isolated (4); hyperglycaemic emergency (2); seizures, cause not
determined (2); acute asthmatic attack (1); efavirenz side-effect (1); deep venous thrombosis (1); haemorrhoids/fistula-in-ano (1),
CD4 < 200 cells/mm3 = 56 illnesses in 44 patients: peripheral neuropathy (12); enteric illness with no pathogen isolated (8); deep venous thrombosis (7);
dermatitis (4); cerebrovascular accident (3); scabies (3); minor traumatic injury (3); pneumothorax (2); pancreatitis (1); cardiomyopathy (1); miscarriage (1);
cryptococcal IRIS (immune reconstitution inflammatory syndrome) adenitis (1); drug induced hepatitis (1); cause not determined but patient subsequently
improved (9).
714 illnesses diagnosed in 11 patients: Drug side effect (3) - hydrochlorothiazide (1), pyrazinamide (1), kanamycin (1); hyperglycaemic emergency (2); post-TB
bronchiectasis (1); peripheral neuropathy (1); pulmonary silicosis (1); miscarriage (1); cause not determined but patient subsequently improved (5)
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follow-up was 82 days (IQR = 48 -125). The CD4+
counts of 46 HIV-1 infected patients who were lost to
follow-up (median 150 cells/μL, IQR = 67-347) did not
differ significantly (P = 0.362) from the CD4+ counts of
147 HIV-1 infected patients who were not lost to fol-
low-up was (median 144 cells/μL, IQR = 66-272).
Discussion
Khayelitsha Site B TB clinic illustrates the successful
integration of public HIV-TB health-care services in
South Africa. These services include voluntary counsel-
ling and testing of HIV status in >95% of TB patients,
drug susceptibility testing on almost all bacteriologic
specimens, trimethoprim-sulfamethoxazole chemopro-
phylaxis in >85% of HIV-1 infected patients, and aggres-
sive ART initiation in HIV-1 infected patients according
to national guidelines. Despite these measures, clinical
deterioration remains an important clinical entity. Dur-
ing the 24 weeks of follow up, 40% of patients experi-
enced clinical deterioration. In multivariate analyses,
significant risk factors for clinical deterioration were
HIV-1 infection and a low CD4+ count at tuberculosis
diagnosis. Currently, HIV-infected patients present to
health care services when they are already profoundly
immune-suppressed. This results in a high burden of
tuberculosis, which is accompanied by multiple compli-
cations during antituberculosis treatment.
A distinct pattern of clinical deterioration emerged dur-
ing the 24 weeks of follow-up (Figure 3). After 10 weeks of
follow-up, we observed a rise in the proportion of patients
with a CD4+ count of 200-350 cells/μL who experienced
clinical deterioration. Few of these patients had initiated
ART (according to national protocol [15]). Further studies
are needed to determine whether ART initiated soon after
tuberculosis diagnosis in this subgroup could reduce the
incidence of clinical deterioration. A triple wave of illnesses
occurred in profoundly immune-suppressed HIV-1
infected patients (CD4+ count < 200 cells/μL). The first
wave (0-4 weeks) comprised co-morbid illnesses and
AIDS-defining illnesses (data not presented). This high-
lights the profound immune-suppression at tuberculosis
diagnosis and the rapid occurrence of AIDS-defining ill-
nesses soon thereafter. The second wave represented co-
morbid illnesses, tuberculosis-related illnesses and non
AIDS-defining HIV-1 related infections, while the third
wave included tuberculosis-related and co-morbid ill-
nesses. This demonstrates that immune restoration during
antituberculosis treatment and ART is not without compli-
cations [7]. The substantial occurrence of co-morbid ill-
nesses throughout the 24 weeks of follow-up was
Figure 2 a: Hazard ratios (95% CI) of risk factors for clinical deterioration during 24 weeks of antituberculosis (TB) treatment in
292 patients (Cox proportional hazards model) and Figure 2b>: Hazard ratios (95% CI) of risk factors for clinical deterioration during
24 weeks of TB treatment in 206 HIV-1 infected patients* (Cox proportional hazards model). *CD4 count not performed in 3 of 209
HIV-1 infected patients (1) Microbiologic confirmation with drug susceptibilities known at TB diagnosis (2) CD4 strata used: Stratum 1 = CD4+
> 350 cells/ μL, stratum 2 = CD4+ from 200 – 350 cells/ μL, stratum 3 = CD4+ < 200 cells/ μL; (3) TMP-SMX chemoprophylaxis = Trimethoprim
sulfamethoxazole 160/800mg daily (4) Antiretroviral treatment regimens as follows: D4T/3TC/EFV (89), D4T/3TC/NVP (3), AZT/3TC/EFV (13),
AZT/3TC/NVP (2), TDF/3TC EFV (2); D4T= stavudine 30mg twice daily, 3TC = lamivudine 150mg twice daily, EFV = efavirenz 600mg nocte,
AZT = zidovudine 300mg twice daily, NVP = nevirapine 200mg twice daily, TDF = tenofovir 300mg daily TB = tuberculosis, DST = drug
susceptibility testing, ART = antiretroviral treatment, P = p-value (significant if < 0.05), 95% CI = 95% confidence interval
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unexpected. Hepatic, renal and cardiovascular related mor-
bidity and mortality are well described in HIV-infected
patients [19]. Similarly, co-morbid illnesses causing
death in HIV-1 uninfected tuberculosis patients have
also been reported [20]. However, the magnitude of
co-morbid illnesses in HIV-1 infected patients receiving
antituberculosis treatment has not previously been
reported. The plethora of illnesses and the 15 deaths
(related to AIDS-defining illnesses, poor adherence, and
neurologic TB-IRIS) suggest that the management of
tuberculosis in profoundly immune-suppressed HIV-1
infected patients is complicated.
Figure 3 Lowess plot showing the proportion of patients who experienced clinical deterioration during 24 weeks of antituberculosis
treatment.
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Preventing the transmission of HIV-1 and preserving
pathogen-specific immunity in those already infected
with HIV-1 (by initiating ART at higher CD4+ counts)
will likely reduce the incidence of tuberculosis. The
potential benefits include fewer deaths and less difficulty
in managing complex drug interactions related to rifam-
pin. However, the massive scale-up of ART to treat
patients at higher CD4+ counts would require consider-
able financial and medical resources. In South Africa,
less than 50% of patients who quality for ART under
current South African guidelines receive ART[15]. Due
to the observational nature of our study, we were unable
to compare the incidence of clinical deterioration after
ART initiation in two groups of tuberculosis patients:
those with a CD4+ count of 200-350 cells/μL and those
with a CD4+ count < 200 cells/μL. Only patients in the
latter group were eligible for ART according to South
African guidelines [15].
Fewer deaths than anticipated occurred during the
first 8 weeks [5]; many deaths (8 of 17) occurred from
weeks 10 to 20 of follow-up. It is possible that patients
with severe tuberculosis may have died in the referral
hospital, precluding enrolment in our study. Patients
requiring hospital admission for fatal AIDS-defining ill-
nesses at tuberculosis diagnosis would similarly have not
been enrolled. Ninety-two (32%) of 292 patients were
diagnosed with tuberculosis at hospital, suggesting that
tuberculosis disease at tuberculosis diagnosis was severe.
Bacterial pneumonia is an important cause of hospita-
lisation and death in HIV-1 infected patients with [21],
or without [22] a diagnosis of tuberculosis. In our
clinic-based cohort, only one patient with pneumonia
cultured a bacterial organism (Haemophilus influenzae).
We attribute this finding to the combined antibacterial
properties of rifampin and trimethoprim-sulfamethoxa-
zole (TMP-SMX) [23]. Most HIV-1 infected patients
(86%) in our study received TMP-SMX chemoprophy-
laxis (160/800 mg daily).
We diagnosed symptomatic drug-induced hepatitis in
one patient. Drug-induced hepatitis, defined as a 5-fold
rise in liver enzymes (AST or ALT), is reported in 2-
28% of patients receiving antituberculosis treatment [24]
and 6% of HIV-1 infected patients receiving both antitu-
berculosis and antiretroviral treatment [25]. In our
study, liver function tests were not performed in asymp-
tomatic patients receiving antituberculosis treatment or
efavirenz-based ART, according to routine practice.
Liver function tests were performed when patients
experienced clinical deterioration.
During the course of our study, DST was performed at
tuberculosis diagnosis, at 8 and 20 weeks of follow-up
and at clinical deterioration. This differs from routine
practice in South Africa where only certain patients
(such as those receiving retreatment for tuberculosis
and those who do not respond to antituberculosis treat-
ment) [14] receive DST due to resource constraints. The
ability to perform DST in all patients in our study,
regardless of previous tuberculosis, likely expedited diag-
nosis and appropriate management of MDR-TB, espe-
cially where the differential diagnoses included MDR-TB
and TB-IRIS.
Our study has some limitations. Our definition of clin-
ical deterioration (symptomatic worsening or failure to
stabilise within 24 weeks after initiation of antitubercu-
losis treatment) did not include episodes of clinical dete-
rioration that occurred after 24 weeks of follow-up.
Twenty-four weeks of follow-up is a short period of
observation. It is possible that the causes for deteriora-
tion could differ after 24 weeks of follow-up. The rela-
tively low number of patients diagnosed with MDR-TB
during follow-up (n = 5) may underestimate the inci-
dence of MDR-TB presenting after 24 weeks. It is note-
worthy that 6 patients were diagnosed with MDR-TB
during the 24 weeks of follow-up without fulfilling our
definition of clinical deterioration. We have previously
described the phenomenon of initial clinical improve-
ment with rifampin-resistant M. tuberculosis despite
receiving standard antituberculosis treatment [26]. At
diagnosis of MDR-TB in these 6 patients, we appropri-
ately intensified their antituberculosis treatment and no
subsequent clinical deterioration occurred. We also
excluded isolated radiological worsening from our case
definition of clinical deterioration. Thus, our finding of
clinical deterioration in 40% of patients may be an
underestimate. Also, in 14 episodes the cause of dete-
rioration could not be identified. Our study did not
evaluate the proportion of patients whose HIV-1 status
was known prior to tuberculosis diagnosis. In addition,
we included patients initially assessed at the tuberculosis
clinic, who subsequently presented to the hospital, and
then deteriorated and died during their first hospital
admission. Patients who presented to the hospital with
fatal tuberculosis may not have been included in the
study. A substantial proportion of patients were lost to
follow-up (75 of 292 patients); reasons for this require
further work. Loss to follow-up did not relate to the
degree of immunosuppression of patients: In HIV-1
infected patients, the CD4+ counts of patients who were
lost to follow-up were similar to the CD4+ counts of
patients who were not lost to follow-up. Finally, this
study was conducted at a tuberculosis clinic and a refer-
ral hospital that serve a large population with a high
incidence of HIV-1-associated tuberculosis; thus, our
findings may not be generalisable to other settings.
Conclusions
The two pandemics of HIV-1 and tuberculosis are inex-
tricably intertwined in Africa. Reducing the extraordinary
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burden of tuberculosis and clinical deterioration during
antituberculosis treatment is a priority for resource-lim-
ited settings. Future prospective studies are required to
determine (1) the optimal interval from antituberculosis
treatment to ART initiation in profoundly immune-sup-
pressed HIV-1 infected patients, and (2) whether ART
initiation during antituberculosis treatment at higher
CD4+ counts reduces the burden of clinical
deterioration.
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